HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Abstract
1. In order to determine whether the renin-angiotensin system is involved in myocardial ischaemia-reperfusion injury, we investigated and compared the effects on infarct size of two different drugs which interfere with this system, i.e., an angiotensin II (AT1) antagonist, EXP3174, and an angiotensin I-converting enzyme inhibitor (ACEI), enalaprilat in a canine model of ischaemia-reperfusion. 2. EXP3174 (0.1 mg kg-1, i.v. followed by 0.02 mg kg-1 h-1 for 5.5 h) and enalaprilate (0.3 mg kg-1, i.v. followed by 0.06 mg kg-1 h-1 for 5.5 h) were used in doses inducing a similar level of inhibition (87 +/- 4 and 91 +/- 3%, respectively) of the pressor responses to angiotensin I. Control animals received saline. 3. Infarct size and area at risk were quantified by ex vivo dual coronary perfusion with triphenyltetrazolium chloride and monastral blue dye. Regional myocardial blood flows (ischaemic and nonischaemic, endocardial, epicardial) were assessed by the radioactive microsphere technique. 4. Both EXP3174 and enalaprilat induced a decrease in mean arterial blood pressure. However, non significant changes in regional myocardial blood flows, whether ischaemic or nonischaemic, were observed after administration of either the ACEI or the AT1 antagonist. 5. The size of the area at risk was similar in the three groups. By direct comparison, there were no significant differences between infarct sizes in the three groups. Furthermore, there was a close inverse relationship between infarct size and transmural mean collateral blood flow in controls, and none of the treatments altered this correlation. Thus, neither EXP3174 nor enalaprilat limited infarct size. 6. These results indicate that activation of the renin-angiotensin system does not contribute to myocyte death in this canine ischaemia/reperfusion model.
AuthorsV Richard, B Ghaleh, A Berdeaux, J F Giudicelli
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 110 Issue 3 Pg. 969-74 (Nov 1993) ISSN: 0007-1188 [Print] England
PMID8298820 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Imidazoles
  • Tetrazoles
  • Angiotensin II
  • Furosemide
  • Angiotensin I
  • losartan carboxylic acid
  • Enalaprilat
  • Losartan
Topics
  • Anesthesia
  • Angiotensin I (pharmacology)
  • Angiotensin II (antagonists & inhibitors)
  • Animals
  • Antihypertensive Agents (therapeutic use)
  • Blood Pressure (drug effects)
  • Coronary Circulation (drug effects)
  • Disease Models, Animal
  • Dogs
  • Enalaprilat (therapeutic use)
  • Female
  • Furosemide (pharmacology)
  • Heart Rate (drug effects)
  • Imidazoles (therapeutic use)
  • Injections, Intravenous
  • Losartan
  • Male
  • Myocardial Infarction (etiology, prevention & control)
  • Myocardial Ischemia (complications, drug therapy)
  • Myocardial Reperfusion Injury (prevention & control)
  • Renin-Angiotensin System (drug effects, physiology)
  • Tetrazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: